"Estrophasic" dosing: A new concept in oral contraceptive therapy

Area of Science:

• Reproductive Endocrinology
• Pharmacology
• Contraception

Background:

• Oral contraceptives are widely used for family planning and managing gynecological conditions.
• There is a continuous need for contraceptive formulations that balance efficacy with reduced side effects.
• Estrogen-related side effects are a common concern with combined oral contraceptives.

Purpose of the Study:

• To evaluate the efficacy, cycle control, and tolerability of a novel estrophasic oral contraceptive, Estrostep.
• To compare Estrostep with a standard monophasic oral contraceptive in terms of cycle control and side effect profile.
• To assess the impact of Estrostep on serum lipid profiles.

Main Methods:

• A double-blind, randomized, parallel-group clinical trial was conducted.
• Participants received either Estrostep (20/30/35 mcg ethinyl estradiol with 1 mg norethindrone acetate) or a 30 mcg ethinyl estradiol monophasic control.
• Serum lipid levels were analyzed in a separate study comparing Estrostep to a triphasic control.

Main Results:

• Estrostep demonstrated acceptable cycle control, comparable to the monophasic control drug.
• The new oral contraceptive was well-tolerated by participants.
• Estrostep showed a neutral impact on serum lipid levels, similar to the triphasic control.

Conclusions:

• Estrostep represents a new estrophasic oral contraceptive design.
• It offers a beneficial low-dose alternative for women seeking hormonal contraception.
• The formulation balances low hormone content with effective cycle control and favorable tolerability.